3月27日 - ** 制药商Ultragenyx Pharmaceutical RARE.O股价上涨2%至38.75美元
** 摩根大通将RARE的目标价从104美元上调至117美元
** 摩根大通将RARE的目标价从104美元上调至117美元。
** 20家券商中有19家将该股评为 "买入 "或更高评级，1家为 "持有"；根据LSEG汇编的数据，他们的目标价中位数为87美元。
** 截至上次收盘，该股今年累计下跌约 10
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.